Close

pCDCAR1 CD20 h(BBζ) (CAR-YF013)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of CD20 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD20. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD20 antibody linked to 4-1BB and CD3ζ signaling domains. And the vector product was designed for the treatment of CD20 positive lymphoma and others.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • CD20
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • CD20 positive Leukemia and Lymphoma
  • Generation
  • Second
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Receptor Construction
  • scFv-4-1BB-CD3ζ
  • Discription of Signaling Cassetes
  • 41BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ, ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • Rituximab
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • membrane spanning 4-domains A1
  • Synonyms
  • B1; S7; Bp35; CD20; CVID5; MS4A2; LEU-16; BA0185

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
Complete CAR data FCM

Fig.1 Rituximab blocks antigen binding of Ab used to derive CAR scFv.

CAR Construction : rituximab scFv-41BB-CD28ζ Latest CAR Construction

Fig.1 Rituximab blocks antigen binding of Ab used to derive CAR scFv.

Ramos cells (CD20þ) were incubated with the indicated rituximab concentrations (conc.) for 30 minutes, followed by incubation with PE-labeled anti-CD20 Ab (clone Leu16) or isotype control at either 4C or 37C for 30 minutes. Cells were washed and analyzed by flow cytometry to determine available CD20 binding sites as measured by PE fluorescence intensity. The panel summarizes the geometric mean fluorescence intensity (MFI) at either 4C or 37C as a function of rituximab concentration.

Rufener, G. A., Press, O. W., Olsen, P., Lee, S. Y., Jensen, M. C., Gopal, A. K., Pender, B., Budde, L. E., Rossow, J. K., Green, D. J., Maloney, D. G., Riddell, S. R., & Till, B. G. (2016). Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. Cancer immunology research, 4(6), 509–519.

Complete CAR data FuncS

Fig.2 Effect of rituximab on CAR T-cell function in vitro.

CAR Construction : rituximab scFv-41BB-CD28ζ Latest CAR Construction

Fig.2 Effect of rituximab on CAR T-cell function in vitro.

The indicated B-cell NHL cell lines were irradiated and incubated for 30 minutes at room temperature with varying rituximab concentrations (at two times the concentrations during incubation to yield the indicated final concentrations after addition of T cells).

Rufener, G. A., Press, O. W., Olsen, P., Lee, S. Y., Jensen, M. C., Gopal, A. K., Pender, B., Budde, L. E., Rossow, J. K., Green, D. J., Maloney, D. G., Riddell, S. R., & Till, B. G. (2016). Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. Cancer immunology research, 4(6), 509–519.

Complete CAR data Cyt

Fig.3 Effect of rituximab on CAR T-cell– mediated cytotoxicity.

CAR Construction : rituximab scFv-41BB-CD28ζ Latest CAR Construction

Fig.3 Effect of rituximab on CAR T-cell– mediated cytotoxicity.

The indicated 51Cr-labeled target cells were preincubated for 30 minutes with rituximab (at two times the concentrations during incubation
to yield the indicated final concentrations after the addition of T cells), and then CD8þ T cells expressing the Leu16-28-z CAR were added at the E:T ratios shown in a standard 5-hour 51Cr-release assay. Mock-transduced T cells and samples with rituximab and target cells only ("0:1") were used as negative controls.

Rufener, G. A., Press, O. W., Olsen, P., Lee, S. Y., Jensen, M. C., Gopal, A. K., Pender, B., Budde, L. E., Rossow, J. K., Green, D. J., Maloney, D. G., Riddell, S. R., & Till, B. G. (2016). Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. Cancer immunology research, 4(6), 509–519.

Complete CAR data FuncS

Fig.4 In vivo effect of rituximab on CD20 CAR T-cell function.

CAR Construction : rituximab scFv-41BB-CD28ζ Latest CAR Construction

Fig.4 In vivo effect of rituximab on CD20 CAR T-cell function.

NSG mice were injected i.v. with 5  105 rituximab-refractory Raji-ffLuc lymphoma cells, followed by one of the following treatments: no treatment, rituximab only (25 mg or 200 mg) i.p. 5 days later, 107 1.5.3-NQ-28-BBz CAR T cells only 6 days after tumor,
or rituximab 25 mg or 200 mg i.p. at 5 days followed by 107 CAR T cells at 6 days after tumor. Mice were imaged twice weekly for bioluminescence.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CD20 (Rituximab) h(4-1BB-CD3ζ) CAR, pCDCAR1 (CAR-YF013). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.